Miller Fisher syndrome following COVID-19 vaccines: A scoping review.
COVID-19 vaccine
Guillain-Barré syndrome
adverse effects
miller Fisher syndrome
systematic review
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
revised:
26
07
2022
received:
01
07
2022
accepted:
31
07
2022
pubmed:
9
8
2022
medline:
18
10
2022
entrez:
8
8
2022
Statut:
ppublish
Résumé
Miller Fisher syndrome (MFS), a variant of Guillain-Barré Syndrome (GBS), could be underestimated in evaluations of its adverse events (AEs) following COVID-19 vaccination. We aimed to identify and characterize MFS following COVID-19 vaccination. Relevant studies reported on during the COVID-19 pandemic were identified in the MEDLINE, Embase, and other databases. Nine cases of MFS following COVID-19 vaccination from various regions were included. Unlike MFS following COVID-19 infection, patients with MFS following COVID-19 vaccination frequently presented with anti-GQ1b antibody positivity (44%, 4/9). Unlike GBS following COVID-19 vaccination, only two of nine (22%) cases of MFS following COVID-19 vaccination had developed after viral-vector-related vaccine administration. Miller Fisher syndrome following COVID-19 vaccination seems to have a different pathophysiology from MFS following COVID-19 infection and GBS following COVID-19 vaccination. This neurological syndrome with a rare incidence and difficulty in diagnosis should be considered an AE of COVID-19 vaccination.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Miller Fisher syndrome (MFS), a variant of Guillain-Barré Syndrome (GBS), could be underestimated in evaluations of its adverse events (AEs) following COVID-19 vaccination. We aimed to identify and characterize MFS following COVID-19 vaccination.
MATERIALS AND METHODS
METHODS
Relevant studies reported on during the COVID-19 pandemic were identified in the MEDLINE, Embase, and other databases.
RESULTS
RESULTS
Nine cases of MFS following COVID-19 vaccination from various regions were included. Unlike MFS following COVID-19 infection, patients with MFS following COVID-19 vaccination frequently presented with anti-GQ1b antibody positivity (44%, 4/9). Unlike GBS following COVID-19 vaccination, only two of nine (22%) cases of MFS following COVID-19 vaccination had developed after viral-vector-related vaccine administration.
CONCLUSIONS
CONCLUSIONS
Miller Fisher syndrome following COVID-19 vaccination seems to have a different pathophysiology from MFS following COVID-19 infection and GBS following COVID-19 vaccination. This neurological syndrome with a rare incidence and difficulty in diagnosis should be considered an AE of COVID-19 vaccination.
Identifiants
pubmed: 35938305
doi: 10.1111/ane.13687
pmc: PMC9539325
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
604-609Subventions
Organisme : This study was supported by grant no. 2020-16 from the Kangdong Sacred Heart Hospital Fund (J. S. B.)
Informations de copyright
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol. 1979;110:105-123.
Wakerley BR, Uncini A, Yuki N. Guillain-Barré and miller Fisher syndromes--new diagnostic classification. Nat Rev Neurol. 2014;10:537-544.
Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255:57-65.
Patone M, Handunnetthi L, Saatci D, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021;27:2144-2153.
Keh RYS, Scanlon S, Datta-Nemdharry P, et al. COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National immunoglobulin database. Brain. 2022;awac067. Online ahead of print.
Frontera JA, Tamborska AA, Doheim MF, et al. Neurological events reported after COVID-19 vaccines: an analysis of VAERS. Ann Neurol. 2022;91:756-771.
Assiri SA, Althaqafi RMM, Alswat K, et al. Post COVID-19 vaccination-associated neurological complications. Neuropsychiatr Dis Treat. 2022;18:137-154.
Kubota T, Hasegawa T, Ikeda K, Aoki M. Case report: isolated, unilateral oculomotor palsy with anti-GQ1b antibody following COVID-19 vaccination. F1000Res. 2021;10:1142.
Nishiguchi Y, Matsuyama H, Maeda K, Shindo A, Tomimoto H. Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination. BMC Neurol. 2021;21:452.
Michaelson NM, Lam T, Malhotra A, Schiff ND, MacGowan DJL. Miller Fisher syndrome presenting after a second dose of Pfizer-BioNTech vaccination in a patient with resolved COVID-19: a case report. J Clin Neuromuscul Dis. 2021;23:113-115.
Dang YL, Bryson A. Miller-Fisher syndrome and Guillain-Barre syndrome overlap syndrome in a patient post Oxford-AstraZeneca SARS-CoV-2 vaccination. BMJ Case Rep. 2021;14:e246701.
Pierre-Yves Sansen EC, Weynants N, Glorieux P. Miller-Fisher syndrome following the first dose of Comirnaty (Pfizer COVID-19 vaccination). J Med Case Rep Case Series. 2021;43:1-3.
Kim JE, Min YG, Shin JY, et al. Guillain-Barré syndrome and variants following COVID-19 vaccination: report of 13 cases. Front Neurol. 2021;12:820723.
Siddiqi AR, Khan T, Tahir MJ, Asghar MS, Islam MS, Yousaf Z. Miller Fisher syndrome after COVID-19 vaccination: case report and review of literature. Medicine (Baltimore). 2022;101:e29333.
Abičić A, Adamec I, Habek M. Miller Fisher syndrome following Pfizer COVID-19 vaccine. Neurol Sci. 2022;43:1495-1497.
Yamakawa M, Nakahara K, Nakanishi T, Nomura T, Ueda M. Miller Fisher syndrome following vaccination against SARS-CoV-2. Intern Med. 2022;61:1067-1069.
Gutiérrez-Ortiz C, Méndez-Guerrero A, Rodrigo-Rey S, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020;95:e601-e605.
Senel M, Abu-Rumeileh S, Michel D, et al. Miller-Fisher syndrome after COVID-19: neurochemical markers as an early sign of nervous system involvement. Eur J Neurol. 2020;27:2378-2380.
Kajani S, Kajani R, Huang CW, Tran T, Liu AK. Miller Fisher syndrome in the COVID-19 era - a novel target antigen calls for novel treatment. Cureus. 2021;13:e12424.
Nachamkin I, Shadomy SV, Moran AP, et al. Anti-ganglioside antibody induction by swine (a/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome. J Infect Dis. 2008;198:226-233.
Anand P, Stahel VP. The safety of Covid-19 mRNA vaccines: a review. Patient Saf Surg. 2021;15:22.
Xu S, Hong V, Sy LS, et al. Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic. Vaccine. 2022;40:3150-3158.